Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 95

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 95
---
 acquisitions.              |

Although we currently anticipate
that we will use the net proceeds from this offering as described above, there may be circumstances where a reallocation of funds is
necessary. Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult to estimate
with certainty the exact amounts of the net proceeds from this offering that may be used for any of the above purposes on a stand-alone
basis. Amounts and timing of our actual expenditures will depend upon a number of factors, including our sales, marketing and commercialization
efforts, regulatory approval and demand for our product candidates, operating costs and other factors described under “Risk Factors”
in this prospectus. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will
not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds
from this offering. For additional information regarding the repayment of the Bridge Loan, see “Certain Relationships and Related
Party Transactions – Other Financings.”

Based on our current plans,
we believe that our existing cash, cash equivalents and short-term deposits, will be sufficient to enable us to fund our operating expenses
and capital expenditure requirements through October 31, 2025. We anticipate that these funds, together with the net proceeds of this
offering, will be sufficient to fund our operating expenses and capital expenditure requirements through March 31, 2027, including the
completion of our pivotal trial for GelrinC with the two-year follow-up required by the FDA. We have based this estimate on assumptions
that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect.

Pending our application of
the net proceeds from this offering, we plan to invest such proceeds in short-term, investment-grade, interest-bearing securities and
depositary institutions.

<div align='center'>DIVIDEND POLICY</div>

We have never declared or
paid any cash dividends to our shareholders of our Ordinary Shares, and we do not anticipate or intend to pay cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors in compliance with applicable
legal requirements and will depend on a number of factors, including future earnings, our financial condition, operating results, contractual
restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable law and other
factors that our board of